Answer
Ultomiris (ravulizumab) is indicated as an add-on to standard therapy for adults with generalised myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody-positive.
Sources for this answer
- Ultomiris 300 mg/3 mL and 1100 mg/11 mL PLGB 31187/0007Alexion Pharma UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 11Document updated
Sources checked